Top-Rated StocksTop-RatedNASDAQ:ABCL AbCellera Biologics (ABCL) Stock Forecast, Price & News $5.00 +0.09 (+1.83%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$4.88▼$5.0050-Day Range$4.91▼$7.9552-Week Range$4.88▼$14.97Volume2.41 million shsAverage Volume2.20 million shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/APrice Target$23.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AbCellera Biologics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside362.5% Upside$23.13 Price TargetShort InterestBearish13.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.51) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector687th out of 968 stocksBiotechnology Industry12th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingAbCellera Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.13, AbCellera Biologics has a forecasted upside of 362.5% from its current price of $5.00.Amount of Analyst CoverageAbCellera Biologics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.37% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 4.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCL. Previous Next 2.5 News and Social Media Coverage News SentimentAbCellera Biologics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AbCellera Biologics this week, compared to 3 articles on an average week.Search InterestOnly 27 people have searched for ABCL on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows23 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 130% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.45% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.39% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.51) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -18.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -18.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AbCellera Biologics (NASDAQ:ABCL) StockAbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Read More ABCL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCL Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comAbCellera Expands Multi-Target Antibody Discovery Collaboration with RegeneronSeptember 19, 2023 | americanbankingnews.comAbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Rating of "Buy" by BrokeragesSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 17, 2023 | americanbankingnews.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Up to $5.17September 15, 2023 | benzinga.comAbCellera Biologics Chief Operating Officer Trades Company's StockSeptember 14, 2023 | finance.yahoo.comInsider Buying: Veronique Lecault Acquires 20,000 Shares of AbCellera Biologics IncAugust 31, 2023 | finance.yahoo.com11 Cheap Small-Cap Stocks to Buy Before the Next BreakoutAugust 31, 2023 | msn.comBenchmark Maintains AbCellera Biologics (ABCL) Buy RecommendationSeptember 22, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 31, 2023 | markets.businessinsider.comWhy AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term ProspectsAugust 31, 2023 | finance.yahoo.com10 Stocks That Could 10X Over the Next 10 YearsAugust 19, 2023 | finance.yahoo.comInstitutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 4.7% drop adds to a year lossesAugust 19, 2023 | finance.yahoo.comBillionaire Stan Druckenmiller’s Small-Cap Stock PicksAugust 10, 2023 | benzinga.comAbCellera Biologics Board Member Makes $177K Stock PurchaseAugust 5, 2023 | msn.comGoldman Sachs Maintains AbCellera Biologics (ABCL) Buy RecommendationAugust 4, 2023 | finance.yahoo.comQ2 2023 Abcellera Biologics Inc Earnings CallAugust 4, 2023 | finance.yahoo.comAbCellera Biologics (ABCL) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | seekingalpha.comAbCellera Biologics Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | finance.yahoo.comAbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue EstimatesAugust 3, 2023 | finance.yahoo.comAbCellera Reports Q2 2023 Business ResultsAugust 2, 2023 | benzinga.comEarnings Preview: AbCellera BiologicsJuly 25, 2023 | finance.yahoo.comDoes AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?July 24, 2023 | stockhouse.comAbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for RehearingJuly 19, 2023 | msn.comAbCellera Biologics: Promising Platform, But Watch-And-Wait Approach AdvisedJuly 14, 2023 | seekingalpha.comWhy did AbCellera Biologics stock dip today? AI-driven rally coolsJuly 6, 2023 | finance.yahoo.comAbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023June 17, 2023 | finance.yahoo.comAbCellera Biologics Insiders Added US$4.2m Of Stock To Their HoldingsSee More Headlines Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCL Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCL CUSIPN/A CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees590Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.13 High Stock Price Forecast$34.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+367.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$158.52 million Net Margins-50.91% Pretax Margin-48.89% Return on Equity-6.05% Return on Assets-4.82% Debt Debt-to-Equity RatioN/A Current Ratio7.83 Quick Ratio7.83 Sales & Book Value Annual Sales$485.42 million Price / Sales2.95 Cash Flow$0.65 per share Price / Cash Flow7.58 Book Value$4.31 per share Price / Book1.15Miscellaneous Outstanding Shares289,360,000Free Float195,460,000Market Cap$1.43 billion OptionableNot Optionable Beta0.01 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Carl L.G. Hansen Ph.D. (Age 48)CEO, Pres & Chairperson Comp: $711.47kMr. Andrew Booth M.B.A. (Age 49)Chief Financial Officer Comp: $642.42kDr. Veronique Lecault Ph.D. (Age 38)COO & Director Comp: $645.07kMr. Tryn T. Stimart Esq. (Age 53)J.D., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Comp: $644.4kMr. Neil Aubuchon M.B.A. (Age 53)Chief Commercial Officer Comp: $684.81kMarcie Thiessen CPACGA, Sr. Director of Fin. & AccountingDr. Ester Falconer Ph.D. (Age 48)Chief Technology Officer Josephine Hellschlienger Ph.D.Mang. of Investor RelationsMs. Tiffany Chiu B.Sc.Ph.D., VP of CommunicationsAlexandra Weirich M.Sc.Mang. of Marketing & CommunicationsMore ExecutivesKey CompetitorsTaro Pharmaceutical IndustriesNYSE:TAROArcus BiosciencesNYSE:RCUSTG TherapeuticsNASDAQ:TGTXIronwood PharmaceuticalsNASDAQ:IRWDCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsBarclays PLCBought 5,443 shares on 9/21/2023Ownership: 0.182%CTC Alternative Strategies Ltd.Bought 18,100 shares on 8/23/2023Ownership: 0.006%Osaic Holdings Inc.Bought 6,371 shares on 8/21/2023Ownership: 0.031%Neo Ivy Capital ManagementBought 47,748 shares on 8/16/2023Ownership: 0.017%Citadel Advisors LLCBought 3,800 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ABCL Stock - Frequently Asked Questions Should I buy or sell AbCellera Biologics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares. View ABCL analyst ratings or view top-rated stocks. What is AbCellera Biologics' stock price forecast for 2023? 8 equities research analysts have issued 12-month target prices for AbCellera Biologics' shares. Their ABCL share price forecasts range from $12.00 to $34.00. On average, they anticipate the company's share price to reach $23.13 in the next twelve months. This suggests a possible upside of 367.2% from the stock's current price. View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts. How have ABCL shares performed in 2023? AbCellera Biologics' stock was trading at $10.13 at the beginning of 2023. Since then, ABCL stock has decreased by 51.1% and is now trading at $4.95. View the best growth stocks for 2023 here. When is AbCellera Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ABCL earnings forecast. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The business had revenue of $10.10 million for the quarter, compared to analysts' expectations of $12.38 million. AbCellera Biologics had a negative net margin of 50.91% and a negative trailing twelve-month return on equity of 6.05%. The firm's revenue for the quarter was down 78.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) EPS. What ETFs hold AbCellera Biologics' stock? ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ). When did AbCellera Biologics IPO? (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO. What is AbCellera Biologics' stock symbol? AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL." Who are AbCellera Biologics' major shareholders? AbCellera Biologics' stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.13%), Capital World Investors (2.91%), Credit Suisse AG (1.58%), ArrowMark Colorado Holdings LLC (1.42%), BlackRock Inc. (1.19%) and Lazard Asset Management LLC (1.13%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AbCellera Biologics' stock price today? One share of ABCL stock can currently be purchased for approximately $4.95. How much money does AbCellera Biologics make? AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.43 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.27) on an earnings per share basis. How many employees does AbCellera Biologics have? The company employs 590 workers across the globe. How can I contact AbCellera Biologics? The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com. This page (NASDAQ:ABCL) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.